Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$264M in Q4 2020 → — now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| NI New Issuer | NaN% | Unchanged | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed October 15, 2026
No position changes this quarter.
quarter ended June 30, 2026 · filed July 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Exited | −223,486 | −$25.7M | — |
| Kymera Therapeutics Inc | Exited | −19,648 | −$1.64M | — |
| Seer Inc | Exited | −816,375 | −$1.54M | — |
| Rallybio Corp | Exited | −94,334 | −$846K | — |
| Sutro Biopharma Inc | Exited | −17,500 | −$436K | — |
| Xilio Therapeutics Inc | Exited | −47,695 | −$401K | — |
| NI New Issuer | New | +0 | — | — |
quarter ended March 31, 2026 · filed May 08, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rallybio Corp | Exited | −754,678 | −$4.14M | — |
| Rallybio Corp | New | +94,334 | +$846K | 2.8% |
| Xilio Therapeutics Inc | Exited | −667,742 | −$427K | — |
| Rapt Therapeutics Inc | Exited | −12,437 | −$421K | — |
| Xilio Therapeutics Inc | New | +47,695 | +$401K | 1.3% |
quarter ended December 31, 2025 · filed February 10, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Trimmed | −824,071 | −$53.7M | 63.9% |
| Kymera Therapeutics Inc | Trimmed | −437,411 | −$34M | 6.7% |
| Sutro Biopharma Inc | Trimmed | −157,500 | −$1.82M | 0.9% |
quarter ended September 30, 2025 · filed November 06, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CT Carisma Therapeutics Inc | Exited | −718,332 | −$281K | — |
quarter ended June 30, 2025 · filed July 10, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics Inc | Trimmed | −87,066 | −$697K | 0.1% |
quarter ended March 31, 2025 · filed April 08, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed April 08, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Trimmed | −333,333 | −$25.6M | 78.2% |
| CT Carisma Therapeutics Inc | New | +718,332 | +$301K | 0.3% |
Loading...
